pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
MEDITOP/2025/01
Phase 1 · other · Comparative bioequivalence study in healthy volunteers under fasting conditions.
MEDITOP/2025/01 for Comparative bioequivalence study in healthy volunteers under fasting conditions. is a Phase 1 program (other) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code MEDITOP/2025/01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 1
- Modality
- other
- Indication
- Comparative bioequivalence study in healthy volunteers under fasting conditions.
- Status
- active
- Trials
- 1